<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05040152</url>
  </required_header>
  <id_info>
    <org_study_id>OSU-21007</org_study_id>
    <secondary_id>NCI-2021-03973</secondary_id>
    <secondary_id>F99CA253745</secondary_id>
    <nct_id>NCT05040152</nct_id>
  </id_info>
  <brief_title>Weight Loss Intervention for the Reduction of Cancer Risk and Health Disparities in Rural Ohio</brief_title>
  <acronym>HERO</acronym>
  <official_title>Address Obesity to Reduce Cancer Risk and Health Disparities in Rural Ohio</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Ohio State University Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study determines the feasibility of a telephone-based weight lost intervention in&#xD;
      reducing cancer risk and health disparities in rural Ohio. Obesity is the leading preventable&#xD;
      cause of cancer, and obesity-related inflammation is linked to elevated cancer risk,&#xD;
      independent of obesity itself. Rural populations are a vulnerable population in need of&#xD;
      increased access to tailored strategies and benefit from weight loss interventions. This&#xD;
      study aims to see whether a telephone-based intervention may help obese people in rural area&#xD;
      to reduce body weight, so as to prevent obesity-related cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the feasibility and acceptability of a 15-week telephone-based weight loss&#xD;
      intervention among overweight/obese rural residents.&#xD;
&#xD;
      II. To estimate the preliminary efficacy of the lifestyle modifications on weight loss, body&#xD;
      composition (fat mass, percent body fat), inflammatory biomarkers (IL-6, TNF-alpha, and&#xD;
      C-recreative protein [CRP]), and other disease risk factors (lipid profiles).&#xD;
&#xD;
      OUTLINE: Participants are randomized to 1 of 2 arms.&#xD;
&#xD;
      ARM I: Participants receive weekly telephone-based weight loss intervention for 15 weeks,&#xD;
      including dietary recommendations tailored to their current weight and weight loss target,&#xD;
      home-based aerobic and resistance exercise, and weekly telephone counseling session over&#xD;
      30-45 minutes.&#xD;
&#xD;
      ARM II: Participants receive education brochures describing the American Institute for Cancer&#xD;
      Research physical activity and dietary guidelines.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 31, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of a 15-week telephone-based weight loss intervention</measure>
    <time_frame>Up to 15 weeks</time_frame>
    <description>Will be defined as the percentage of enrolled participants who complete the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in body weight (KG)</measure>
    <time_frame>Up to 15 weeks</time_frame>
    <description>Changes in body weight (KG)will be measured by a weight scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in body fat mass</measure>
    <time_frame>Up to 15 weeks</time_frame>
    <description>Changes in body fat mass will be measured using a 3-Dimension (3D) Body Scanner, Styku S100</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes body fat percentage</measure>
    <time_frame>Up to 15 weeks</time_frame>
    <description>Changes body fat percentage will be measured using a 3-Dimension (3D) Body Scanner, Styku S100</description>
  </other_outcome>
  <other_outcome>
    <measure>Lipid profiles</measure>
    <time_frame>Up to 15 weeks</time_frame>
    <description>Total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) will be obtained by fasting capillary blood sampling from fingerstick and analyzed using Cholestech LDX</description>
  </other_outcome>
  <other_outcome>
    <measure>C-reactive protein (CRP) concentration (ng/L)</measure>
    <time_frame>Up to 15 weeks</time_frame>
    <description>C-reactive protein (CRP) concentration (ng/L) will be quantified with an automated chemistry analyzer</description>
  </other_outcome>
  <other_outcome>
    <measure>Interleukin (IL)-6 concentration (pg/mL)</measure>
    <time_frame>Up to 15 weeks</time_frame>
    <description>Interleukin (IL)-6 concentration (pg/mL) will be quantified with sandwich enzyme immunoassay assays</description>
  </other_outcome>
  <other_outcome>
    <measure>TNF-alpha concentration (pg/mL)</measure>
    <time_frame>Up to 15 weeks</time_frame>
    <description>TNF-alpha concentration (pg/mL) will be quantified with sandwich enzyme</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical fitness</measure>
    <time_frame>Up to 15 weeks</time_frame>
    <description>Participants will be asked to complete two valid and reliable timed performance-related mobility tasks, including 400-meter walk and lift and carry task</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical activity</measure>
    <time_frame>Up to 15 weeks</time_frame>
    <description>Self-reported using Leisure-Time Exercise Questionnaires118. Objectively measured physical activity will be recorded using the LIFECORDER Plus Accelerometer for 7 days in the 1st and 15th week</description>
  </other_outcome>
  <other_outcome>
    <measure>Exercise-Related Self-Efficacy Exercise-Related</measure>
    <time_frame>Up to 15 weeks</time_frame>
    <description>Assessed by using Exercise Self-Efficacy, Barrier Self-Efficacy, and Multi-dimensional Self-Efficacy scales</description>
  </other_outcome>
  <other_outcome>
    <measure>Dietary intake</measure>
    <time_frame>Up to 15 weeks</time_frame>
    <description>Self-reported using the National Institutes of Health Daily Food List</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Obesity-Related Malignant Neoplasm</condition>
  <arm_group>
    <arm_group_label>Arm I (telephone-based intervention)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive weekly telephone-based weight loss intervention for 15 weeks, including dietary recommendations tailored to their current weight and weight loss target, home-based aerobic and resistance exercise, and weekly telephone counseling session over 30-45 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (education brochures)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive education brochures describing the American Institute for Cancer Research physical activity and dietary guidelines.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Dietary Counseling and Surveillance</intervention_name>
    <description>Receive dietary recommendations</description>
    <arm_group_label>Arm I (telephone-based intervention)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Exercise Intervention</intervention_name>
    <description>Complete home exercises</description>
    <arm_group_label>Arm I (telephone-based intervention)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Informational Intervention</intervention_name>
    <description>Receive education brochures</description>
    <arm_group_label>Arm II (education brochures)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (telephone-based intervention)</arm_group_label>
    <arm_group_label>Arm II (education brochures)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Telephone-Based Intervention</intervention_name>
    <description>Receive telephone-based weight loss intervention</description>
    <arm_group_label>Arm I (telephone-based intervention)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index (BMI) &gt;= 25 kg/m^2&#xD;
&#xD;
          -  Age: 20-64.9 years&#xD;
&#xD;
          -  Not currently participating in any weight loss intervention or meet the physical&#xD;
             activity recommendation (150 min/week of moderate-intensity exercise or 75 min/week of&#xD;
             vigorous exercise)&#xD;
&#xD;
          -  The ability to walk two blocks&#xD;
&#xD;
          -  Ability to speak and read English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior cancer diagnosis (except non-melanoma skin cancer) or severe medical conditions&#xD;
             such as unstable cardiovascular disease or digestive disorders that would preclude&#xD;
             physical activity and dietary intervention&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
&#xD;
          -  Unable to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian C Focht, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>The Ohio State University Comprehensive Cancer Center</last_name>
    <phone>800-293-5066</phone>
    <email>OSUCCCClinicaltrials@osumc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian C. Focht, PhD</last_name>
      <phone>614-292-2165</phone>
      <email>bfocht@ehe.osu.edu</email>
    </contact>
    <investigator>
      <last_name>Brian C. Focht, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancer.osu.edu</url>
    <description>The Jamesline</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 25, 2021</study_first_submitted>
  <study_first_submitted_qc>September 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2021</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University Comprehensive Cancer Center</investigator_affiliation>
    <investigator_full_name>Brian Focht</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

